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Abstract
The emergence of fluconazole-resistant Candida (FRC) is worrisome, but little is known about susceptibility patterns in different noso-
comial settings. We prospectively analysed Candida bloodstream isolates in 18 medical centres in Israel (six tertiary-care and 12 commu-
nity hospitals). The study included 444 episodes of candidaemia (450 patient-specific isolates, 8.5% fluconazole-resistant). Institutional
FRC bloodstream infection rates correlated with annual inpatient days, and were strongly associated with the presence and activity of
haematology/oncology services. Infection with Candida krusei and fluconazole-resistant Candida glabrata occurred exclusively in hospitals
with >600 beds. These findings suggest that empirical antifungal strategies should be tailored to the nosocomial setting.
Keywords: Candidaemia, drug resistance, epidemiology, fluconazole
Original Submission: 2 May 2012; Revised Submission: 8 August 2012; Accepted: 14 August 2012
Editor: E. Roilides
Article published online: 30 August 2012
Clin Microbiol Infect 2013; 19: 752–756
10.1111/1469-0691.12004
Corresponding author: R. Ben-Ami, Infectious Disease Unit, Tel
Aviv Sourasky Medical Centre, 6 Weizman St., Tel Aviv 64239, Israel
E-mail: ronenba@tasmc.health.gov.il
*Listed in Appendix I.
Candidaemia is a serious nosocomial infection that carries
significant morbidity and mortality [1,2]. Epidemiological sur-
veys have revealed regional variations in candidaemia inci-
dence rates, species distribution, drug-resistance patterns
and mortality rates [3–14]. However, even within a defined
geographical region, candidaemia may occur in widely dispa-
rate settings, from small community hospitals with basic inpa-
tient care facilities to large tertiary centres that provide
highly specialized services. Nevertheless, little is known
about the characteristics of Candida spp. in different nosoco-
mial settings.
We performed a prospective nationwide hospital labora-
tory-based survey of candidaemia in Israel from November
2005 through to June 2007 [15]. Eighteen medical centres,
which together account for 75% of the acute-care hospital
beds in Israel, were included: six tertiary-care hospitals
(6002 beds), and 12 smaller community hospitals (5678
beds). Hospitals were located in northern (n = 7), central
(n = 9) and southern (n = 2) districts of Israel. Ten hospitals
were clustered in three urban zones: zone A (greater Tel
Aviv area, four hospitals), zone B (Jerusalem, three hospitals)
and zone C (Haifa, three hospitals).
Demographic and clinical data were prospectively entered
into standardized data forms by on-site investigators and
reviewed by the principle investigator. Candida isolates were
sent to the central study site for species identification using
standard microbiology methods. Susceptibility to fluconazole,
voriconazole, amphotericin B and caspofungin was deter-
mined using the E-test (bioMerieux, Marcy l’Etoile, France)
method. Because of trailing growth with the E-test, C. glabrata
fluconazole susceptibility was determined using broth micro-
dilution according to CLSI method M27-A3 [16]. We used
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the recently updated CLSI species-specific antifungal drug
susceptibility thresholds [17–19]. The study was approved by
the ethics committees of each participating centre.
Candidaemia incidence rates were calculated using data
obtained from the Israeli Ministry of Health (http://
www.health.gov.il). We analysed the correlation between
fluconazole-resistant Candida (FRC) bloodstream infection
and hospital volume of activity and the availability and activity
of specialized services. Hospital and patient variables that
were found to interact significantly with fluconazole-resis-
tance in bivariable analyses were entered into a multivariable
logistic regression model in a stepwise fashion, and those
variables with a significant effect on the b coefficient
(p <0.05) were retained in the model. The time-at-risk (num-
ber of calendar days from the date of hospital admission to
the date of candidaemia) was forced into the multivariable
model. Chi-squared test or Fisher’s exact test and Student’s
t test were used to assess the distribution of categorical and
continuous variables, respectively. A type I error of <0.05
was considered statistically significant. Calculations were per-
formed in STATA 11.1 (StataCorp, College Station, TX, USA).
The study included 444 patients and 450 patient-specific
Candida isolates (Table 1). The adjusted incidence rates of
candidaemia were 11/100 000 inpatient-days, 5.57/100 000
population/year. The most frequent species were C. albicans,
(n = 200, 44.4%), C. parapsilosis (n = 75, 16.6%), C. tropicalis
TABLE 1. Demographic and clinical characteristics of patients with candidaemia by hospital size
Characteristic
Hospital size
Odds ratio (95% CI) p Total<600 beds >600 beds
Medical centres 9 (50) 9 (50) 18 (100)
Tertiary-care centre 0 (0) 6 (67) NA 0.009 6 (33)
Urban zone
A 0 (0) 4 (44) NA 4 (22)
B 2 (22) 1 (11) 0.4 3 (17)
C 2 (22) 1 (11) 0.4 3 (17)
Other 5 (55) 3 (33) 0.4 0.20 8 (44)
Patient days/year, mean (SD)
Intensive care 2772 (2629) 6017 (3658) NA 0.04 79 096 (3512)
Oncology 0 (0) 11 147 (7573) NA 0.002 100 323 (7738)
HSCT 0 (0) 2394 (2992) NA 0.058 19 150
Total 130 733 (48 302) 319 446 (82 755) NA <0.0001 4 051 613 (117 249)
Patients with candidaemia 94 (21.1) 356 (80.1) 444 (100)
Gender
Male 49 (53) 189 (54) 1.0 (0.6–1.6) 0.9 238 (53.6)
Female 44 (47) 162 (46) 0.9 206 (46.4)
Age, median (IQR), years 70 (49–79) 62 (32–76) NA <0.0001 65 (33–77)
Functional disabilitya 39 (51) 138 (47) 0.8 (0.4–1.4) 0.6 177 (48.1)
Days in hospital, median (IQR)b 14 (6–27) 16 (6–30) NA 0.3 15 (6–30)
Inpatient service
Medicine 35 (37.6) 110 (31.3) 0.7 (0.4–1.2) 0.2 145 (32.6)
Surgery 21 (22.5) 76 (21.6) 0.9 (0.5–1.7) 0.8 74 (16.6)
Intensive care 52 (55.9) 145 (41.3) 0.5 (0.3–0.9) 0.01 197 (44.4)
Haematology/oncology 4 (4.3) 49 (13.9) 3.6 (1.2–14.1) 0.01 53 (11.9)
Charlson score, median (IQR) 3 (1–6) 3 (2–6) NA 0.8 3 (2–6)
Malignancy
Leukaemia 0 (0) 34 (9.6) 2.5c 0.001 34 (7.6)
Lymphoma 5 (5.3) 18 (5.1) 0.9 (0.3–3.3) 1.0 23 (5.1)
Solid tumour 16 (17.2) 97 (27.6) 1.8 (1.0–3.5) 0.04 113 (25.4)
Diabetes mellitus 28 (30.1) 80 (22.7) 0.6 (0.4–1.1) 0.1 108 (24.3)
Renal failure 10 (10.7) 50 (14.2) 1.3 (0.6–3.1) 0.5 60 (13.5)
Antimicrobial exposurec 83 (89.2) 327 (93.1) 1.6 (0.6–3.7) 0.2 410 (92.3)
Azole exposurec 11 (11.8) 48 (13.6) 1.1 (0.5–2.6) 0.7 59 (13.2)
Central vascular catheter 66 (70.9) 265 (75.5) 1.2 (0.7–2.1) 0.4 331 (74.5)
Parenteral nutrition 32 (34.4) 115 (32.7) 0.9 (0.5–1.5) 0.8 147 (33.1)
Mechanical ventilationc 52 (55.9) 147 (41.8) 0.5 (0.3–0.9) 0.02 199 (44.8)
Surgeryc 39 (41.9) 136 (38.7) 0.8 (0.5–1.4) 0.6 175 (39.4)
Abdominal surgery 23 (24.7) 64 (18.2) 0.6 (0.3–1.2) 0.1 87 (19.6)
Chest surgery 5 (5.3) 21 (5.9) 1.1 (0.3–3.9) 1.0 26 (5.8)
Cytotoxic chemotherapyc 6 (6.4) 76 (21.6) 4.0 (1.6–11.6) 0.0008 82 (18.5)
Neutropeniac 3 (3.2) 51 (14.5) 5.1 (1.5–26.0) 0.003 54 (12.2)
Renal replacement therapy 9 (9.6) 30 (8.5) 0.8 (0.3–2.1) 0.6 39 (8.7)
Prematurity 10 (10.7) 19 (5.4) 0.4 (0.2–1.1) 0.09 29 (6.5)
Stem cell transplant 0 (0) 22 (6.2) 1.6d 0.01 22 (5.0)
Solid organ transplant 1 (1.0) 3 (0.8) 0.7 (0.06–42.0) 1.0 4 (0.9)
HSCT, haematopoietic stem-cell transplant; IQR, interquartile range; NA, not applicable.
All values denote number of patients (percentage), except where specified otherwise. p values are for Fisher’s exact test for categorical variables and Student’s t test for sca-
lar variables. Values in bold represent variables that were significantly differently distributed between small (<600 beds) and large (>600 beds) hospitals.
aDefined as partial or complete dependence on others for activities of daily living.
bTime (days) from date of hospital admission to date of first blood culture positive for Candida spp.
cWithin 30 days before the onset of candidaemia.
dOdds ratio calculated with the Cornfield method. Confidence interval cannot be detrmined because there were no cases in patients from hospitals with <600 beds.
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(n = 77, 17.1%), C. glabrata (n = 69, 15.3%), and C. krusei
(n = 14, 3.1%). Six patients had dual-species candidaemia.
Fifty-four candidaemia episodes (12.1%) were caused by iso-
lates non-susceptible to fluconazole: 16 (3.6%) susceptible
dose-dependent and 38 (8.5%) FRC.
Seven centres (38.8%) had oncology services and five
(27.7%) had stem-cell transplantation services (Table 1). FRC
were found in ten hospitals (rate of resistance in those
institutions, 7.1–13.6%). Hospitals where FRC were detected
had significantly more total acute beds than hospitals with no
FRC—median (interquartile ranges), 752 (657–970) beds ver-
sus 405 (310–465) beds, respectively; p 0.009). FRC were
detected in 2/9 hospitals (22%) with <600 beds but in 8/9
hospitals (88%) with >600 beds (Fig. 1). The pooled inci-
dence of candidaemia was marginally greater in larger hospi-
tals than in smaller ones (11.9 versus 7.3/100 000 patient-
days, p 0.050). However, the incidence rate of FRC blood-
stream infection was nearly ten-fold higher in larger hospitals
(1.2 versus 0.14/100 000 patient-days, p 0.0004). Moreover,
there was a significant linear correlation between hospital
volume (annual inpatient-days) and the incidence rate of FRC
bloodstream infection (Pearson’s coefficient, 0.73, p 0.0005).
Fluconazole-resistant C. glabrata and C. krusei occurred exclu-
sively in hospitals with >600 beds: 0.23 versus 0/100 000
patient-days for C. glabrata (p 0.02), and 0.44 versus 0/
100 000 patient-days for C. krusei (p 0.009; Fig. 1). Resistance
(a) (b)
(c) (d)
FIG. 1. Incidence rates of candidaemia by hospital size. Each marker represents a single medical centre. (a) Incidence rates of all candidaemia
episodes; (b) incidence rates of fluconazole-resistant Candida bloodstream infection; (c) incidence rates of Candida krusei bloodstream infection;
(d) incidence rates of fluconazole-resistant Candida glabrata bloodstream infection. Vertical dashed line marks the median hospital size of 600
beds.
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rates to voriconazole, caspofungin and amphotericin B were
not significantly different between low-volume and high-vol-
ume hospitals.
Demographic and clinical features of patients with candida-
emia varied with hospital size. Hospitalization at a hospital
with >600 beds was associated with younger age, care in a
haematology/oncology service, leukaemia, solid neoplasm,
cytotoxic chemotherapy, neutropenia and haematopoietic
stem-cell transplantation (Table 1).
Three covariates were retained in the multivariable model
with FRC bloodstream infection as the dependent variable:
neutropenia (odds ratio 3.6, 95% confidence interval 1.6–8.2;
p 0.002), receipt of fluconazole within 30 days before candida-
emia (OR 4.1, 95% CI 1.8–9.2; p <0.0001) and hospitalization
at a medical centre with >600 beds (OR 4.4, 95% CI 1.006–
19.5; p 0.049). Goodness-of-fit for this model was adequate as
determined using the Hosmer–Lemeshow test (p 0.5).
In this nationwide study in Israel, candidaemia was a fre-
quent nosocomial event, but the proportion of FRC was highly
variable across different medical centres, even among those in
close geographical proximity. Strikingly, divergent epidemio-
logical patterns were observed in low-volume and high-vol-
ume institutions. Hence, although the candidaemia rate was
only slightly higher in high-volume institutions, bloodstream
infection with FRC occurred almost exclusively at high-volume
institutions. FRC infection was strongly associated with the
oncological and stem-cell transplantation settings, which were
limited to large, tertiary-care medical centres.
Our study underscores the need for nationwide studies
that incorporate data from diverse nosocomial settings and a
range of hospital types [2,8,9,15]. Candidaemia surveillance
programmes often only include data from tertiary-care medi-
cal centres [3,7,10,14], a design that may select for patient
populations at high risk for drug-resistant Candida spp.,
resulting in potential overestimation of the overall incidence
rate of drug resistance.
In conclusion, this study, the first of its kind performed in
the Middle East, illustrates the epidemiology of candidaemia
in Israel and highlights the importance of tertiary-care medi-
cal centres, and specifically that of haematology/oncology
units, as hotspots for the emergence of FRC. These findings
may be used to direct empirical treatment strategies at the
institutional level.
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Appendix I: Additional Israeli Candidaemia
Study Group Invesigators
Tel Aviv Sourasky Medical Centre, Tel Aviv: Ruth Orni-Was-
serlauf; Hadassah-Hebrew University Medical Centre, Jerusa-
lem: Allon Moses, Karen Olshtain-Pops; Chaim Sheba Medical
Centre, Tel Hashomer: Michal Krieger, Yasmin Maor, Anna
Goldshmidt-Reuven; Rambam Medical Centre, Haifa: Renato
Finkelstein, Hannah Sprecher; Rabin Medical Centre and
Schneider Children’s Hospital, Petah Tikva: Michal Paul, Itzhak
Levi, Zmira Samra, Elad Goldberg; Wolfson Medical Centre,
Holon: Michael Dan, Orna Schwartz-Harari; Shaare Zedek
Medical Centre, Jerusalem: Amos Yinon, Yonit Weiner Well;
Assaf Harofeh Medical Centre, Zerifin: Tsilia Lazarovitch;
Kaplan Medical Centre, Rehovot: Oren Zimhony; Meir Medical
Centre, Kfar Saba: BatSheva Gottesman; Bnai Zion Medical
Centre, Haifa: Israel Potasman; Emek Medical Centre, Afula:
Raul Raz, Bibiana Chazan; Soroka Medical Centre, Beer Sheva:
Klaris Riesenberg, Lisa Saidel; Bikur Holim Medical Centre,
Jerusalem: Efraim Halperin; Hillel Yafe Medical Centre, Hadera:
David Hassin; Poriya Medical Centre, Tiberias: Soboh Soboh.
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